retlirafusp alfa

News

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.